Superworth

Gilead Sciences price to sales ratio GILD

Market value divided by revenue over the last twelve months, since 2010.

Today, Oct 23, 2026
6.4×
10-year median
3.7×
Against its 10-year history
99th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.7× to 6.6×
Peer median
5.8×

Gilead Sciences' price to sales ratio is 6.4× as of Oct 23, 2026.

That is above its ten-year median of 3.7×, higher than on 99% of days in the last ten years.

Over that time it ranged from 2.7× in Mar 2022 to 6.6× in Feb 2026.

The median for 8 large drugmakers of a similar size is 5.8×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.4×5.2×6.6×
20255.3×4.0×5.4×
20244.1×2.9×4.3×
20233.7×3.4×4.1×
20224.0×2.7×4.1×
20213.3×3.0×3.7×
20203.2×3.1×4.7×
20193.7×3.5×4.1×
20183.6×3.3×4.3×
20173.4×2.8×3.9×
20163.0×3.0×4.4×
20154.6×4.6×7.7×
20146.8×6.8×11.9×
201310.7×6.2×10.8×
20125.9×3.9×6.2×
20113.8×3.4×4.4×
20103.7×3.5×4.4×

Against its peers

Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first, today.

CompanyPrice to sales ratio
GILDGilead Sciences6.4×
PFEPfizer2.7×
AMGNAmgen6.2×
BMYBristol-Myers Squibb2.6×
MRKMerck5.4×
ABBVAbbVie7.8×
JNJJohnson & Johnson6.4×
BIIBBiogen3.7×
LLYEli Lilly and15.0×
Peer median5.8×

Where Gilead Sciences ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Gilead Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.